Congestive heart failure acute pharmacotherapy

Congestive Heart Failure Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Systolic Dysfunction Diastolic Dysfunction HFpEF HFrEF
Causes
Differentiating Congestive heart failure from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Cardiac MRI
Echocardiography
Exercise Stress Test
Myocardial Viability Studies
Cardiac Catheterization
Other Imaging Studies
Other Diagnostic Studies
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy:
Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF Diuretics ACE Inhibitors Angiotensin receptor blockers Aldosterone Antagonists Beta Blockers Ca Channel Blockers Nitrates Hydralazine Positive Inotropics Anticoagulants Angiotensin Receptor-Neprilysin Inhibitor Antiarrhythmic Drugs Nutritional Supplements Hormonal Therapies Drugs to Avoid Drug Interactions Treatment of underlying causes Associated conditions
Exercise Training
Surgical Therapy: Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) Implantation of Intracardiac Defibrillator Ultrafiltration Cardiac Surgery Left Ventricular Assist Devices (LVADs) Cardiac Transplantation
ACC/AHA Guideline Recommendations Initial and Serial Evaluation of the HF Patient Hospitalized Patient Patients With a Prior MI Sudden Cardiac Death Prevention Surgical/Percutaneous/Transcather Interventional Treatments of HF Patients at high risk for developing heart failure (Stage A) Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B) Patients with current or prior symptoms of heart failure (Stage C) Patients with refractory end-stage heart failure (Stage D) Coordinating Care for Patients With Chronic HF Quality Metrics/Performance Measures
Implementation of Practice Guidelines
Congestive heart failure end-of-life considerations
Specific Groups: Special Populations Patients who have concomitant disorders Obstructive Sleep Apnea in the Patient with CHF NSTEMI with Heart Failure and Cardiogenic Shock
Congestive heart failure acute pharmacotherapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congestive heart failure acute pharmacotherapy
CDC on Congestive heart failure acute pharmacotherapy
Congestive heart failure acute pharmacotherapy in the news
Blogs on Congestive heart failure acute pharmacotherapy
Directions to Hospitals Treating Congestive heart failure acute pharmacotherapy
Risk calculators and risk factors for Congestive heart failure acute pharmacotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: acute decompensated heart failure, ADHF, flash pulmonary edema

Overview

Acute heart failure can occur in the setting of a new onset heart failure or worsening of an existing chronic heart failure (also known as acute decompensated heart failure, flash pulmonary edema, ADHF). ADHF presents with acute shortness of breath due to the development of pulmonary edema (the rapid accumulation of fluid in the lung). Other signs and symptoms of ADHF include hypotension with impaired and organ perfusion manifested by worsening renal function, altered mentation and cold clammy extremities. ADHF associated with a poor prognosis if not treated aggressively. Like chronic heart failure therapy, the goal is to improve symptoms but unlike chronic therapy the other goals are to improve oxygenation and hemodynamic stability. The mainstays of the acute medical treatment in acute decompensated congestive heart failure include oxygen to improve hypoxia, diuresis to reduce both preload and intravascular volume and vasodilators to reduce afterload. Some of the mainstays of chronic heart failure therapy are not initiated acutely (ACE inhibtors,beta blockers and digoxin).

General Recommendations

Hospitalization

Hospitalization is required for the management of the patient with ADHF with the following signs, symptoms and laboratory abnormalities:

• Hypotension and/or cardiogenic shock
• Evidence of poor end organ perfusion such as worsening renal function, cold clammy extremities, altered mental status
• Hypoxemia with an oxygen saturation under 90%
• Atrial fibrillation with a rapid ventricular response resulting in hypotension
• The possible presence of an acute coronary syndrome and ongoing myocardial ischemia

Telemetry and Monitoring

The patient should be admitted to a level of care that allows for constant electrocardiographic monitoring given the risk of arrhythmias and frequent vital signs.

• The heart rhythm and oxygen saturation should be monitored continuously.
• Is and Os (intake and output) should be monitored carefully. A daily target should be established (for example the patient should be one liter negative for the day) and diuretic dosing should be adjusted to achieve this target.
• Daily weights should be obtained using the same scale at the same time of the day, usually before the patient has eaten, and after they have first voided in the morning. Often times Is and Os measurements will underestimate insensible losses that occur through the lungs.
• The BUN and creatinine, serum sodium(to detect hyponatremia which carries a poor prognosis), chloride, bicarbonate (to detect contraction alkalosis) and serum potassium (to detect hypokalemia as a result of diuresis and which can precipitate arrhythmias) should be monitored daily. Potassium and magnesium should be repeated as needed following diuresis.

Medical Therapy

Systolic Versus Diastolic Heart Failure

The management of the patient with acute decompensated heart failure depends upon whether the patient has acute decompensated systolic heart failure or acute decompensated diastolic heart failure. Both forms of acute decompensated heart failure are treated with oxygen and vasodilator therapy and diuresis. Importantly, inotropic agents that increase contractility are not indicated in the patient with acute decompensated diastolic heart failure while they are important for the patient with acute decompensated systolic heart failure. While beta blocker initiation is relatively contraindicated in acute decompensated systolic heart failure, control of tachycardia is very useful in the patient with diastolic heart failure to prolong left ventricular filling time. While the initiation of ACE inhibitors may not be recommended in acute decompensated systolic heart failure, ACE inhibition may be of benefit in acute decompensated diastolic heart failure.

Treatment Goals

• Reduce preload
• Reduce afterload
• Reduce intravascular volume
• Improve cardiac contractility

Management Plan

Oxygen

• Oxygen improves the patient's status if hypoxemia is present. Continuous positive airway pressure may be applied using a face mask; this has been shown to improve symptoms more quickly than oxygen therapy alone, and has been shown to reduce the risk of death. Severe respiratory failure requires treatment with endotracheal intubation and mechanical ventilation.

Diuretics

• Diuretics reduce preload and reduce intravascular volume. Intravenous diuretics are often required in the acute setting. If high doses of furosemide are inadequate, boluses or continuous infusions of bumetanide may be preferred. These loop diuretics may be combined with thiazide diuretics such as oral metolazone or intravenous chlorthiazide for a synergistic effect. Intravenous preparations are preferred because of more predictable absorption. When a patient is extremely fluid overloaded, they can develop intestinal edema as well, which can affect enteral absorption of medications.

Nitroglycerine

• Nitroglycerine reduces afterload and reduces preload. Nitroglycerine is helpful in improving symptoms of dyspnea.

Morphine

• Morphine reduces preload, reduces catecholamines, and reduces the stimulation by stretch receptors in the lung thereby improving symptoms of dyspnea.

More Aggressive Pharmacotherapy

• Nitroprusside reduces afterload and reduces preload
• Ionotropes may be administered if the patient's circulatory volume is adequate but there is persistent evidence of inadequate end-organ perfusion.
• Milrinone increases contractility and reduces afterload
• Dobutamine increases contractility in reduces afterload
• Dopamine increases blood pressure and increases renal perfusion at low doses
• Nesiritide reduces afterload and reduces preload and can be used if other therapies have not been effective.

Arrhythmias

Atrial Fibrillation

Atrial fibrillation can cause acute decompensation of heart failure due to an increase in heart rate and oxygen demands, and conversely acute decompensation of heart failure can precipitate atrial fibrillation due to left atrial dilation and increased wall stress. Thus, atrial fibrillation and acute decompensated heart failure are often intimately related, and the successful management of atrial fibrillation is often critical to the success of reversing the acute decompensation.

In the patient with acute decompensated heart failure, rate control of atrial fibrillation is the mainstay of arrhythmia therapy. Obviously agents that have a negative inotropic effect such as beta blockers and non-dihydropyridine calcium channel blockers are relatively contraindicated in the management of acute decompensated systolic heart failure. Intravenous diltiazem does not have a negative inotropic effect and is often used for rate control. Short acting esmolol is sometimes used. Digoxin has a very narrow therapeutic/toxic window, it's onset of action is relatively delayed, and it is often not used.

If a patient is in cardiogenic shock, then cardioversion can be considered in the patient with new onset atrial fibrillation, however in the absence of severe hemodynamic compromise it should be noted that atrial fibrillation will often recur in this setting. Thus, cardioversion is not particularly helpful in the absence of profound hemodynamic compromise.

References

Template:WikiDoc Sources